In line with this, in a study of 109 patients with relapsed MM, circulating levels of BNP > 100 pg/mL or NT-proBNP > 125 pg/mL before the initiation of carfilzomib were associated with an odds ratio of 10.8 for subsequent CV adverse events [89]. This evidence concerns the gene NPPB and Miyoshi myopathy.